Requires that an intravascular bleed monitor -- which uses measurements of the body's electrical conductivity and an algorithm to monitor potential internal bleeding complications -- be subject to special controls from the U.S. Food and Drug Administration. Those controls require performance testing for efficacy, usability, and safety; software verification, validation, and hazard analysis; and detailed labeling.
Requires that the Saranas Early Bird Bleed Monitoring System -- a device that uses measurements of the body's electrical conductivity and an algorithm to monitor potential internal bleeding complications -- be subject to special controls from the U.S. Food and Drug Administration. Those controls include the following:
Requires performance testing demonstrating that the device meets standards for efficacy, safety, sterility, and usability.
Requires software verification, validation, and hazard analysis to be performed.
Requires detailed product labeling to include instructions for use and storage, among other product details.
Key facts
🏛️ This document has been enacted by the U.S. Food and Drug Administration.
For authoritative text and metadata, visit the official source.
🎯 This document primarily applies to the private sector, rather than the government.
📜 This document's name is 21 CFR § 870.1345 ("Intravascular bleed monitor").
Themes
AI risks, applications, governance strategies, and other themes addressed in AGORA documents.
This tag applies to documents that discuss evaluations that assess whether deployed AI systems meet the expectations specified or claimed prior to deployment.
This tag applies to documents that require, incentivize, or otherwise encourage actors involved in AI-related activities, such as AI developers, vendors, users, or researchers, to either receive sanction from a regulator for their activities (licensing, certification) or to notify a regulator of their activity pursuant to a formal process (registration).
This tag applies to documents that require or incentivize AI systems to incorporate specific features or achieve (or not achieve) specified results in operation, or to be used or not to be used in specified ways or for specific purposes. Requirements may be defined objectively (e.g., systems must score above a certain level on an established benchmark, systems must incorporate a certain technical feature) or subjectively (e.g., systems must not demonstrate undue bias).
This is an unofficial copy. The document has been
archived and reformatted in plaintext for AGORA. Footnotes, tables, and
similar material may be omitted. For the official text, visit the original source.
§ 870.1345 Intravascular bleed monitor.
(a) Identification.
An intravascular bleed monitor is a probe, catheter, or catheter introducer that measures changes in bioimpedance and uses an algorithm to detect or monitor progression of potential internal bleeding complications.
Identifies an intravascular bleed monitor as a device detecting internal bleeding via bioimpedance changes.
Identifies an intravascular bleed monitor as a device detecting internal bleeding via bioimpedance changes.
(b) Classification.
Class II (special controls). The special controls for this device are:
(1) In vivo animal performance testing must demonstrate that the device performs as intended under anticipated conditions of use and evaluate the following:
(i) Device performance characteristics;
(ii) Adverse effects, including gross necropsy and histopathology; and
(iii) Device usability, including device preparation, device handling, and user interface.
(2) Non-clinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following
performance characteristics must be tested:
(i) Tensile testing of joints and materials;
(ii) Mechanical integrity testing;
(iii) Friction testing;
(iv) Flush testing;
(v) Air leakage and liquid leakage testing;
(vi) Latching and unlatching testing;
(vii) Kink and bend testing;
(viii) Insertion force testing;
(ix) Torque testing;
(x) Corrosion testing; and
(xi) Dimensional tolerance testing.
Requires special controls for Class II devices, including in vivo animal and non-clinical performance testing.
Requires special controls for Class II devices, including in vivo animal and non-clinical performance testing.
(3) Performance data must support the sterility and pyrogenicity of the device components intended to be provided sterile.
(4) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
(5) The patient contacting components of the device must be demonstrated to be biocompatible.
(6) Software verification, validation, and hazard analysis must be performed.
(7) Performance data must demonstrate electromagnetic compatibility (EMC), electrical safety, thermal safety, and mechanical safety.
(8) Human factors performance evaluation must demonstrate that the user can correctly use the device, based solely on reading the directions for use.
(9) Labeling must include:
(i) Instructions for use;
(ii) A shelf life and storage conditions;
(iii) Compatible procedures;
(iv) A sizing table; and
(v) Quantification of blood detected.
Requires performance data to support sterility, shelf life, biocompatibility, software safety, and user instructions.
Requires performance data to support sterility, shelf life, biocompatibility, software safety, and user instructions.